De-Escalation Strategy Produces ‘Favorable’ Outcomes in Oropharyngeal Carcinoma
Reducing the radiotherapy dose and target volume to subclinical regions produced “favorable clinical outcomes,” according to researchers.
Reducing the radiotherapy dose and target volume to subclinical regions produced “favorable clinical outcomes,” according to researchers.
The incidence of oropharyngeal cancer in men increased 2.7% per year.
Under a status quo scenario based on current levels of HPV vaccination, 792,000 OPC cases in men would be prevented by the year 2100.
The 2-year progression-free survival rate exceeded 90% for all treatment arms.
Findings suggest a need for tailored treatment in oropharyngeal squamous cell carcinoma.
Investigators tested the efficacy of reduced-dose radiation plus cisplatin in patients with good-risk human papillomavirus–associated oropharyngeal squamous cell carcinoma (OPSCC).
This analysis identified the factors for poor long-term survival in radiotherapy (RT)-treated patients with oropharyngeal cancer (OPC).
Outcomes and survival improved for early-stage oropharyngeal cancer, but not other cancers.
Single-center study reports on the effects of oropharyngeal cancer treatment at 3, 6, and 12 months after chemoradiotherapy or radiotherapy alone, and with and without a feeding tube.
This study assessed causes of early mortality stratified by HPV status in oropharynx cancer.